Literature DB >> 22098833

Surgery for gastric cancer: what the trials indicate.

Scott A Hundahl1.   

Abstract

To optimize the therapeutic value of an operation for cancer, surgeons must weigh survival value against mortality/morbidity risk. As a result of several prospective, randomized trials, many surgeons feel that international opinion has reached a consensus. Reflexively radical surgical hubris has certainly given way to a more nuanced, customized approach to this disease. But issues remain. This article critically reviews existing data and emphasizes areas of continued controversy. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22098833     DOI: 10.1016/j.soc.2011.09.005

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  2 in total

1.  Problems faced by evidence-based medicine in evaluating lymphadenectomy for gastric cancer.

Authors:  Giuseppe Verlato; Simone Giacopuzzi; Maria Bencivenga; Paolo Morgagni; Giovanni De Manzoni
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

2.  Risk factors associated with splenic hilar lymph node metastasis in patients with advanced gastric cancer in northwest China.

Authors:  Zhenqiang Sun; Qisan Wang; Xianbo Yu; Chunlin Ou; Lizhong Yao; Kun Liu; Lin Liu; Lei Ge; Fa Fang; Zeliang Zhao; Haijiang Wang
Journal:  Int J Clin Exp Med       Date:  2015-11-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.